Get the Stockscreener App
23.59
1.13%
-0.27
Pre-market:
24.34
0.75
+3.18%
Immunovant Inc stock is traded at $23.59, with a volume of 1.68M.
It is down -1.13% in the last 24 hours and down -8.78% over the past month.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
See More
Previous Close:
$23.86
Open:
$24.03
24h Volume:
1.68M
Relative Volume:
1.87
Market Cap:
$3.99B
Revenue:
-
Net Income/Loss:
$-323.01M
P/E Ratio:
-10.63
EPS:
-2.22
Net Cash Flow:
$-272.30M
1W Performance:
+3.10%
1M Performance:
-8.78%
6M Performance:
-15.66%
1Y Performance:
-41.57%
1-Day Range:
$23.10
$24.42
1-Week Range:
$23.10
$25.29
52-Week Range:
$22.41
$41.38
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
23.59 | 3.99B | 0 | -323.01M | -272.30M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Immunovant's chief medical officer sells $56,782 in stock - MSN
Immunovant CEO Peter Salzmann sells $208,899 in stock - MSN
Peter Salzmann Sells 8,767 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) CFO Sells $54,761.34 in Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $56,786.89 in Stock - MarketBeat
Immunovant's chief medical officer sells $56,782 in stock By Investing.com - Investing.com Australia
Immunovant CFO Eva Renee Barnett sells $54,756 in stock By Investing.com - Investing.com Canada
Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential - Yahoo Finance
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Bank of America Issues Pessimistic Forecast for Immunovant (NASDAQ:IMVT) Stock Price - Defense World
Bank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock Price - MarketBeat
JPMorgan Chase & Co. Lowers Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
JPMorgan Chase & Co. Sells 28,586 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.22 Average Price Target from Analysts - MarketBeat
How to Take Advantage of moves in (IMVT) - Stock Traders Daily
Insider Buying: Immunovant, Inc. (NASDAQ:IMVT) Director Buys 16,845,010 Shares of Stock - MarketBeat
Roivant sciences increases stake in Immunovant with $336.9 million purchase By Investing.com - Investing.com Nigeria
Roivant sciences increases stake in Immunovant with $336.9 million purchase - Investing.com
Immunovant to raise $450M from institutional investors - MSN
Immunovant Progresses in Autoimmune Therapy Development - TipRanks
Immunovant (NASDAQ:IMVT) Hits New 12-Month LowWhat's Next? - MarketBeat
Immunovant Raises $450 Million Through Share Purchase Agreement - TipRanks
Immunovant Announces $450 Million Private Placement - The Manila Times
Immunovant Secures Massive $450M Private Placement to Accelerate Drug Development - StockTitan
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $47.22 - MarketBeat
Q1 Earnings Estimate for Immunovant Issued By Zacks Research - Defense World
Immunovant CFO Eva Renee Barnett sells $98,930 in stock - Investing.com India
Immunovant CFO Eva Renee Barnett sells $98,930 in stock By Investing.com - Investing.com Australia
Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett Sells 4,105 Shares - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) CEO Peter Salzmann Sells 5,105 Shares - MarketBeat
Warm Autoimmune Hemolytic Anemia (wAIHA) Clinical - openPR
Immunovant stock hits 52-week low at $23.86 amid challenges By Investing.com - Investing.com Nigeria
Myasthenia Gravis Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen R&D, Immunovant - The Globe and Mail
Immunovant (NASDAQ:IMVT) Reaches New 52-Week LowHere's Why - MarketBeat
Immunovant stock hits 52-week low at $23.86 amid challenges - Investing.com India
Myasthenia Gravis Market Poised for Significant Growth from - openPR
(IMVT) Long Term Investment Analysis - Stock Traders Daily
Immunovant (NASDAQ:IMVT) Lowered to “Peer Perform” Rating by Wolfe Research - Defense World
Immunovant (NASDAQ:IMVT) Shares Gap DownHere's What Happened - MarketBeat
Wolfe Research Downgrades Immunovant (NASDAQ:IMVT) to Peer Perform - MarketBeat
Immunovant (NASDAQ:IMVT) Shares Up 4.1%Here's Why - MarketBeat
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth - Yahoo Finance
Immunovant stock hits 52-week low at $24.61 amid market challenges - Investing.com Canada
RSI Alert: Immunovant (IMVT) Now Oversold - Nasdaq
Immunovant stock hits 52-week low at $24.61 amid market challenges By Investing.com - Investing.com South Africa
Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study (NASDAQ:IMVT) - Seeking Alpha
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):